KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $209.0 billion.

  • Pfizer's Liabilities and Shareholders Equity fell 477.32% to $209.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $836.5 billion, marking a year-over-year decrease of 534.59%. This contributed to the annual value of $213.4 billion for FY2024, which is 599.3% down from last year.
  • As of Q3 2025, Pfizer's Liabilities and Shareholders Equity stood at $209.0 billion, which was down 477.32% from $206.1 billion recorded in Q2 2025.
  • In the past 5 years, Pfizer's Liabilities and Shareholders Equity ranged from a high of $227.0 billion in Q4 2023 and a low of $41.1 billion during Q4 2022
  • For the 5-year period, Pfizer's Liabilities and Shareholders Equity averaged around $185.6 billion, with its median value being $206.1 billion (2025).
  • Per our database at Business Quant, Pfizer's Liabilities and Shareholders Equity crashed by 1121.83% in 2022 and then skyrocketed by 42269.49% in 2023.
  • Quarter analysis of 5 years shows Pfizer's Liabilities and Shareholders Equity stood at $181.5 billion in 2021, then increased by 8.67% to $197.2 billion in 2022, then increased by 15.11% to $227.0 billion in 2023, then decreased by 5.99% to $213.4 billion in 2024, then dropped by 2.06% to $209.0 billion in 2025.
  • Its last three reported values are $209.0 billion in Q3 2025, $206.1 billion for Q2 2025, and $208.0 billion during Q1 2025.